Oxalinamo contains Oxaliplatin, an intravenous platinum-based chemotherapeutic agent used primarily for the treatment of colorectal cancer. It is often administered in combination with other chemotherapy drugs, such as 5-fluorouracil (5-FU) and leucovorin (FOLFOX regimen), to enhance anticancer efficacy. Oxaliplatin works by damaging DNA in cancer cells, which inhibits their replication and induces cell death.

Mechanism of Action

• Oxaliplatin forms platinum-DNA adducts, creating cross-links between DNA strands.

• This prevents DNA replication and transcription, leading to cancer cell apoptosis.

• It primarily affects rapidly dividing tumor cells while sparing most normal cells.

  Uses

  • Treatment of colorectal cancer (both adjuvant and metastatic settings).

  • Used in combination regimens such as FOLFOX for enhanced efficacy.

  • Sometimes used off-label for other gastrointestinal cancers.

  • Helps slow tumor progression and improve survival in advanced colorectal cancer.

    Adverse Effects

    • Peripheral neuropathy (tingling, numbness, or pain in hands/feet)

    • Nausea, vomiting, diarrhea

    • Fatigue or weakness

    • Low blood counts (anemia, neutropenia, thrombocytopenia)